The biggest approval headlines of the past week came from well-established molecules, as the US FDA cleared a major new indication outside of diabetes for AstraZeneca PLC’s Farxiga and a higher-dose nasal spray formulation of the opioid antagonist naloxone, Hikma Labs Inc.’s Kloxxado.
The agency had closed out the previous week with a novel oncology agent from ADC Therapeutics SA, Zynlonta, bringing...





